Skip to main content

When older adults with MS should stop drugs remains unclear

By MS Buddy ·

Summarized from Journal of the neurological sciences, Nov 2026 · PubMed. AI-generated summary. Not medical advice.

24 people · MS specialists in Israel

Research by Keren Regev, Tamir Ben-Hur and 20 colleagues at Neurology Institute, Barzilai Medical Center and 10 other institutions in Israel.

When do MS specialists think older adults should stop treatment?

Key Takeaway

Israeli MS specialists agreed that older adults need treatment decisions based on more than age, but they remained unsure when treatment should stop.

Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
Credibility
Interest
Share:1 min read

What They Found

Specialists agreed that treatment decisions for older adults with MS should weigh possible benefits and risks. They viewed continuing, reducing, or stopping treatment as possible choices for some older adults whose MS is stable. They remained unsure how best to stop treatment. They also reported uncertainty about treatment decisions when progressive MS shows no current signs of new disease activity. Their views favored considering disease activity, scan results, safety, other health conditions, and patient preferences.

Who Should Care and Why

The study surveyed MS specialists in Israel, not people with MS. It focused on decisions about care for older adults with MS. The specialists discussed whether treatment should continue, be reduced, or stop. They also considered decisions about progressive MS. Their answers show where specialists agreed and where they remained uncertain.

Important Considerations

This was a two-round survey completed by 24 MS specialists. It reports expert opinions, not results from testing treatment choices in patients. You should not read these findings as formal treatment advice or as the views of specialists worldwide.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Journal of the neurological sciences by et al.. Reproduced from the PubMed record.

The aging population of people with multiple sclerosis (MS) presents growing clinical challenges that are insufficiently addressed by existing evidence. Age-related changes in disease biology, treatment effectiveness, and safety complicate therapeutic decision-making, particularly regarding treatment de-escalation and discontinuation. To describe areas of agreement and uncertainty among Israeli MS specialists regarding clinical decision-making for older adults with MS. A national two-round modified Delphi survey was conducted among 24 MS specialists in Israel. Round 1 included 23 items spanning age-related considerations, late-onset MS (LOMS), treatment continuation, de-escalation and discontinuation, progressive MS, monitoring, vaccination, and treatment decision factors. A structured expert discussion was followed by a focused second round. Consensus definitions were prespecified before response analysis after review of published Delphi methodology and were tailored to item structure. All 24 specialists completed both Delphi rounds. Panel characteristics were subsequently provided by 23 participants (95.8%): median experience in MS care was 15 years (range, 3-35), median annual MS caseload was 500 patients (range, 100-800), 22 practiced primarily in academic or hospital-based settings, and one reported mixed academic and community practice. The panel endorsed age-specific risk-benefit assessment, recognized continuation, de-escalation, and discontinuation as legitimate options in selected stable older patients, and identified persistent uncertainty regarding exit strategies and non-active progressive disease. These findings describe national expert opinion rather than evidence-based recommendations. This national modified Delphi survey describes areas of agreement and uncertainty among Israeli MS specialists. The findings support individualized treatment decisions integrating inflammatory activity, radiologic stability, safety, comorbidity burden, and patient preference, rather than age alone. They should not be interpreted as international consensus or as formal treatment recommendations.

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Rounded stem cells with visible nuclei float against a muted blue-gray background.
MS stem cell transplants mostly done without admission

11/19/2026

A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be

Read More
Nerve fibers with segmented myelin coverings, including a few areas where the covering is missing.
MS rates varied widely across North and South America

11/19/2026

A review of 50 studies found wide differences in MS rates across the Americas. MS became more common

Read More
Two clusters of paper speech bubbles contain varied patchwork shapes on one side and orderly layers on the other.
MS side effect posts showed two communication styles

11/20/2026

A study of online MS medication discussions found two main styles: sharing personal experiences and

Read More
Paper bands support a bowl of blue droplets; a few drops sit outside, and a dotted path leads to a guiding hand.
Remotely guided muscle training eased urine leaks in MS

11/20/2026

A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac

Read More
Paper vegetables and a walking shoe beside unfinished paths that stop short of a cluster of cell-like circles.
MS review: diet and exercise links need more evidence

11/18/2026

A review finds limited direct evidence that diet, exercise, or gut microbes affect MS through the bo

Read More
A myelin-wrapped nerve fiber beside branching paths that continue beyond view, with no preferred route marked.
Choosing a first MS treatment brought fear and doubt

11/19/2026

Interviews with 17 people newly diagnosed with relapsing-remitting MS explored fear, doubt, and unce

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.